[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 36 of about 36
1. Jackevicius A, Cicenas S, Naujokaitis P, Piscikas D: [Diagnosis and treatment of pleural mesothelioma]. Medicina (Kaunas); 2002;38 Suppl 2:79-81
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of pleural mesothelioma].
  • The objective of our paper was to show the data of our treated patients with malignant pleural mesothelioma.
  • In the Department of Thoracic Surgery of Oncology Institute at Vilnius University from 1980 till 01.06.2002, 33 patients (pts), to whom diagnosis of pleural mesothelioma was confirmed by pathologist, were treated in the Clinic.
  • A malignant pleural mesothelioma was diagnosed in 31 pts, two pts had a non-malignant form of mesothelioma.
  • The distribution of pts according to the stage of the disease was: I stage - 3, II - 1, III - 17, IV - 10.
  • Videothoracoscopy is the best method for diagnosing pleural mesothelioma.
  • Adjuvant therapy (chemotherapy or radiotherapy) was given to 10 pts.
  • Diagnosis of malignant pleural mesothelioma is difficult and confirmation of the disease is possible only after histological examination of tumor.
  • 2. The best results of treatment were achieved after combined treatment: surgery, after chemotherapy and radiotherapy.
  • 3. In cases of pleural effusion of diffuse pleural mesothelioma insufflation of talc or other chemical substances into pleural cavity is recommended.
  • [MeSH-major] Mesothelioma. Pleural Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pleura / pathology. Pneumonectomy. Radiotherapy, Adjuvant. Survival Analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12560629.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Lithuania
  •  go-up   go-down


2. El Hossieny HA, Aboulkasem F, Abdel Rahman M: Analysis of the effect of radiotherapy on malignant pleural mesothelioma when given on adjuvant or palliative basis. Zhongguo Fei Ai Za Zhi; 2010 Jan;13(1):54-9
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the effect of radiotherapy on malignant pleural mesothelioma when given on adjuvant or palliative basis.
  • BACKGROUND AND OBJECTIVE: This retrospective study was designed to evaluate the response and survival of malignant pleural mesothelioma to radiotherapy when delivered with surgery and chemotherapy and when delivered alone or with chemotherapy.
  • METHODS: A study for 110 patients with malignant pleural mesothelioma who presented to radiotherapy department, National Cancer Institute, Cairo and received radiation therapy in the period fromJanuary 1999 to July 2007.
  • RESULTS: Forty-six patients (41.8%) received trimodality therapy (surgery & adjuvant or neoadjuvant chemotherapy & adjuvant radiotherapy), while bimodality therapy (chemotherapy & radiotherapy) in 38 patients (34.5%), while 26 patients (23.6%) received single modality therapy (palliative radiotherapy), 22 patients (20%) developed local recurrence, 22 patients (20%) developed distant metastases months, 14 patients (12.7%) developed local disease progression, 25 patients (22.7%) are still alive and free of disease at time of reporting.
  • The median survival for all patients was 16 months, while 12 and 18 months overall survival were 63.6% & 31.8% respectively while median survival for stage II, III, IV patients was 16.5, 12.5 and 8 months respectively.
  • CONCLUSION: Multimodality approach involving surgery, chemotherapy and radiotherapy have been evaluated and proved its superiority in improving survival, especially in stages II.
  • [MeSH-major] Combined Modality Therapy / methods. Mesothelioma / drug therapy. Mesothelioma / radiotherapy. Pleural Neoplasms / drug therapy. Pleural Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / methods. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy / methods. Radiotherapy, Adjuvant / methods. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20672705.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


3. Gupta V, Krug LM, Laser B, Hudka K, Flores R, Rusch VW, Rosenzweig KE: Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy. J Thorac Oncol; 2009 Jun;4(6):746-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy.
  • INTRODUCTION: Multimodality therapy including extrapleural pneumonectomy (EPP), chemotherapy, and radiotherapy (RT) is often recommended for fit patients with early stage malignant pleural mesothelioma.
  • We studied patterns of local and nodal recurrence in patients treated at our institution with EPP and RT, and whether advanced treatment planning techniques, such as intensity modulated radiotherapy (IMRT), could have been of potential benefit.
  • METHODS: From 1993 to 2008, 86 patients with malignant pleural mesothelioma underwent EPP followed by hemithoracic RT (median dose: 54 Gy).
  • The RT technique included a combination of photons and electrons to maximize dose to the target, whereas minimizing dose to normal tissues.
  • After treatment, patients were followed with serial imaging and patterns of local and nodal failure were studied.
  • RESULTS: Median follow-up time for 78 analyzed patients was 17 months.
  • Eight percent were in stage I, 35% stage II, 55% stage III, and 2% stage IV.
  • Ten percent of all patients developed late grade 3 pulmonary toxicity and no patient died of RT.
  • [MeSH-major] Mesothelioma / radiotherapy. Mesothelioma / surgery. Neoplasm Recurrence, Local / pathology. Photons. Pleural Neoplasms / radiotherapy. Pleural Neoplasms / surgery. Pneumonectomy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy, Intensity-Modulated. Retrospective Studies. Survival Rate. Treatment Failure

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404212.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Katsuragi N, Shiraishi Y, Kita H, Toishi M, Miyasaka Y, Tanaka S: [Diffuse malignant pleural mesothelioma]. Kyobu Geka; 2007 Jan;60(1):35-9
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diffuse malignant pleural mesothelioma].
  • Malignant pleural mesothelioma is an uncommon neoplasm that caused 647 deaths in Japan in 2004.
  • We reviewed the clinical features in 11 consecutive patients with pathologically confirmed diffuse malignant pleural mesothelioma in our institution from January 1997 to December 2002.
  • A definitive diagnosis was made by closed pleural biopsy in 8 patients, pleural fluid cytology in 2, and autopsy in 1.
  • International Mesothelioma Interest Group (IMIG) staging included stage II in 6 patients, stage III in 3, and stage IV in 2.
  • Treatment included intrapleural chemotherapy in 4 patients, extrapleural pneumonectomy in 3, pleural drainage in 2, and best supportive care in 2.
  • Median survival time after diagnosis was 3 (range, 0 to 51) months.
  • [MeSH-major] Mesothelioma. Pleural Neoplasms

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17249536.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Matsuzaki Y, Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T: Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma. Ann Thorac Cardiovasc Surg; 2008 Jun;14(3):161-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma.
  • PURPOSE: Despite extensive clinical research, no effective therapy for advanced malignant pleural mesothelioma has been established.
  • In this study, we induced apoptosis in patients with this disease, using intrapleural perfusion hyperthermo-chemotherapy, a new procedure developed in our surgical department.
  • MATERIAL AND METHODS: Our study included 6 consecutive patients with malignant pleural mesothelioma (stage III: 5; stage IV: 1).
  • Because of the advanced stage of the disease, none of the patients underwent tumor resection or pleurectomy.
  • All patients, however, received perfusion treatment.
  • The patients had a median survival time of 30 months.
  • No patient morbidity was associated with the perfusion treatment.
  • CONCLUSION: In patients with malignant pleural mesothelioma, intrapleural perfusion hyperthermo-chemotherapy induced potent apoptosis of tumor cells, increasing immediately postperfusion and peaking at 24 h.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Cisplatin / therapeutic use. Hyperthermia, Induced. Mesothelioma / therapy. Perfusion. Pleural Neoplasms / therapy
  • [MeSH-minor] Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Pleural Effusion, Malignant / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18577894.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, Smith IE, O'Brien ME: Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer; 2004 May 17;90(10):1905-11
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
  • To examine whether weight loss at presentation influences outcome in patients who received chemotherapy for lung cancer or mesothelioma.
  • Data were available for age, gender, performance status, histology, stage, response, toxicity, progression-free and overall survival.
  • The outcomes of patients with or without weight loss treated with chemotherapy for small cell lung cancer (SCLC; n=290), stages III and IV non-small-cell lung cancer (NSCLC; n=418), or mesothelioma (n=72) were compared.
  • Weight loss was reported by 59, 58 and 76% of patients with SCLC, NSCLC and mesothelioma, respectively.
  • Patients with weight loss and NSCLC (P=0.003) or mesothelioma (P=0.05) more frequently failed to complete at least three cycles of chemotherapy.
  • Mesothelioma patients with weight loss had fewer symptomatic (P=0.03) and objective responses (P=0.05).
  • Weight loss was an independent predictor of shorter overall survival for patients with SCLC (P=0.003, relative risk (RR)=1.5), NSCLC (P=0.009, RR=1.33) and mesothelioma (P=0.03, RR=1.92) and an independent predictor of progression-free survival in patients with SCLC (P=0.01, RR=1.43).
  • In conclusion, weight loss as a symptom of lung cancer predicts for toxicity from treatment and shorter survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Mesothelioma / drug therapy. Mesothelioma / pathology. Weight Loss

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Weight Control.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1980 Jul;65(1):25-32 [6930515.001]
  • [Cites] Bone Marrow Transplant. 1995 Mar;15(3):461-8 [7599573.001]
  • [Cites] Cancer. 1983 Jun 1;51(11):2005-12 [6301671.001]
  • [Cites] Cancer. 1986 Sep 15;58(6):1378-86 [3091243.001]
  • [Cites] J Clin Oncol. 1986 Nov;4(11):1604-14 [3021920.001]
  • [Cites] J Clin Oncol. 1987 Jan;5(1):113-24 [3027267.001]
  • [Cites] J Clin Oncol. 1987 Feb;5(2):185-9 [3027268.001]
  • [Cites] Cancer Res. 1989 Oct 15;49(20):5748-54 [2790789.001]
  • [Cites] Cancer Res. 1990 Feb 15;50(4):1125-31 [2297761.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):899-905 [2159056.001]
  • [Cites] Eur J Cancer. 1991;27(1):9-15 [1826450.001]
  • [Cites] Br J Cancer. 1991 Jun;63(6):986-92 [1648949.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):623-31 [10653877.001]
  • [Cites] Acta Oncol. 1999;38(8):1011-5 [10665754.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):523-33 [10931451.001]
  • [Cites] Thorax. 2000 Sep;55(9):731-5 [10950889.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1336-43 [11230476.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2600-5 [7595713.001]
  • [Cites] Thorax. 1997 Apr;52(4):338-41 [9196516.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):145-52 [9440736.001]
  • [Cites] Chest. 1998 Mar;113(3):723-31 [9515850.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):269-73 [9602260.001]
  • [Cites] Br J Cancer. 1998 Jun;77(11):1966-70 [9667676.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 6;91(1):66-72 [9890172.001]
  • [Cites] Lung Cancer. 1999 Feb;23(2):153-8 [10217619.001]
  • [Cites] Clin Sci (Lond). 1999 Aug;97(2):215-23 [10409477.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3188-94 [10506617.001]
  • [Cites] Am J Clin Oncol. 1999 Oct;22(5):453-7 [10521057.001]
  • [Cites] Cancer Detect Prev. 1998;22(4):293-304 [9674872.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3210-8 [11432888.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):601-3 [11786593.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3749-57 [12552988.001]
  • [Cites] Lung Cancer. 2003 Mar;39(3):303-13 [12609569.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Cancer. 1991 Oct 1;68(7):1616-21 [1654199.001]
  • [Cites] Eur J Cancer. 1991;27(7):866-70 [1657078.001]
  • [Cites] Nutrition. 1990 May-Jun;6(3):233-40 [2152097.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):2043-9 [8410128.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6430-3 [7987838.001]
  • [Cites] Br J Cancer. 1995 Feb;71(2):366-70 [7530988.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1221-30 [7738625.001]
  • [Cites] Lancet. 1995 Mar 4;345(8949):535-9 [7776771.001]
  • [Cites] Am J Med. 1980 Oct;69(4):491-7 [7424938.001]
  • (PMID = 15138470.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2409471
  •  go-up   go-down


7. Flores RM, Krug LM, Rosenzweig KE, Venkatraman E, Vincent A, Heelan R, Akhurst T, Rusch VW: Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol; 2006 May;1(4):289-95
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial.
  • INTRODUCTION: Extrapleural pneumonectomy (EPP) and adjuvant high-dose radiation therapy (RT) are associated with a median survival of 3 years in early-stage malignant pleural mesothelioma (MPM) but of less than 1 year in locally advanced disease.
  • We designed this clinical trial to test the feasibility of induction chemotherapy followed by EPP and RT in locally advanced MPM with the ultimate aim of improving survival.
  • METHODS: Patients with MPM and stage III or IV disease were eligible.
  • Induction therapy was four cycles of gemcitabine and cisplatin.
  • Patients without disease progression by computed tomography underwent EPP followed by adjuvant hemithoracic RT (54 cGy).
  • Pretreatment disease stage was III in 13 patients and IV in six patients.
  • Nineteen patients received induction chemotherapy.
  • Response to induction therapy was complete in zero patients, partial in five patients, stable disease in six patients, and progression of disease in eight patients.
  • CONCLUSION: Induction chemotherapy with gemcitabine and cisplatin followed by EPP and adjuvant RT for locally advanced MPM is feasible and leads to a better median overall survival than that previously reported with EPP and RT alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / therapy. Pleural Neoplasms / therapy. Pneumonectomy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409872.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Liu F, Zhao B, Krug LM, Ishill NM, Lim RC, Guo P, Gorski M, Flores R, Moskowitz CS, Rusch VW, Schwartz LH: Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans. J Thorac Oncol; 2010 Jun;5(6):879-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans.
  • PURPOSE: The purposes of this study were (1) to calculate the tumor volume in patients with malignant pleural mesothelioma using computed tomography (CT) scan images and a computer-aided measurement technique and (2) to investigate whether the baseline volume, or volume change after chemotherapy, predicts patient survival.
  • METHODS: We compiled the clinical characteristics and outcome from 30 patients enrolled in two clinical trials at our cancer center in which the patients were treated with induction chemotherapy followed by surgery and radiation.
  • CT scans of 30 patients were obtained at baseline and after two cycles of chemotherapy.
  • Overall survival was measured using a landmark time at 3 months post-treatment start date such that all patients had already received two cycles of chemotherapy and a follow-up scan.
  • The relationship between both pre and postoperative clinical stage and baseline tumor volume was analyzed using the rank sum test.
  • Patients with high preoperative stages (III and IV) had larger baseline tumor volume than those with low preoperative stages (I and II) (p = 0.05).
  • Percentage change of tumor volume from baseline to first follow-up CT after two cycles of chemotherapy was significantly associated with overall survival (hazard ratio: 1.94 [95% confidence interval, 1.05-3.60], p = 0.04).
  • By classifying changes of tumor volumes between two scans into two groups, i.e., "increase" and "decrease," a significant difference in survival was found between those who increased and decreased after two cycles of chemotherapy (p = 0.03).
  • CONCLUSIONS: Changes in tumor volume after two cycles of chemotherapy predicted overall survival in patients with malignant pleural mesothelioma.
  • Tumor volume at baseline was shown to be associated with preoperative clinical stage and survival.
  • Computer-aided volumetric measurements may enable more reliable therapeutic response assessment and could provide additional prognostic information.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy. Tomography, X-Ray Computed / methods. Tumor Burden
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20421814.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Passot G, Cotte E, Brigand C, Beaujard AC, Isaac S, Gilly FN, Glehen O: [Peritoneal mesothelioma: treatment with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy]. J Chir (Paris); 2008 Sep-Oct;145(5):447-53
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peritoneal mesothelioma: treatment with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy].
  • [Transliterated title] Mésothéliome péritonéal: traitement par l'association chirurgie de cytoréduction et chimiothérapie hyperthermique intrapéritonéale.
  • Diffuse malignant peritoneal mesothelioma is a rare and lethal disease.
  • Locoregional treatments combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) seem to improve prognosis.
  • RESULTS: Nineteen patients with diffuse malignant peritoneal mesothelioma were included (16 epithelial, 3 biphasic and 3 multicystic forms).
  • Sixteen patients presented stage 3 or 4 peritoneal mesothelioma according to the Gilly classification.
  • No post-operative deaths occurred but 9 patients (47%) presented grade III or IV post-operative complications.
  • CONCLUSION: Cytoreductive surgery combined with HIPEC may improve the length of survival for patients with diffuse malignant peritoneal mesothelioma; such patients should be treated in specialized centers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Mesothelioma / drug therapy. Mesothelioma / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106865.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Yoon HE, Nonaka K, Fukuhara K, Ueshima H, Sugiura T, Kaneda H, Shimamoto S, Imakita M, Iwase K: [Extrapleural pneumonectomy of malignant pleural mesothelioma]. Kyobu Geka; 2004 Oct;57(11):1011-5
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extrapleural pneumonectomy of malignant pleural mesothelioma].
  • We analyzed 7 patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy.
  • According to staging of International Mesothelioma Interest Group, 2 patients had stage I disease, 1 did stage II, 3 did stage III and 1 did stage IV.
  • In patients with local recurrences, 2 had irradiation with chemotherapy and 1, irradiation.
  • In patients with recurrences of metastasis, 1 had chemotherapy and 1, supportive care.
  • Extrapleural pneumonectomy with adjuvant therapy could be effective treatment for malignant pleural mesothelioma.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery. Pneumonectomy / methods

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15510813.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Uramoto H, Shimokawa H, Baba T, Shigematsu Y, Nagata Y, Ono K, Takenoyama M, Hanagiri T: [Experience in treating patients with malignant pleural mesothelioma]. J UOEH; 2010 Sep 1;32(3):257-64
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experience in treating patients with malignant pleural mesothelioma].
  • The objective of this study was to analyze the outcome of patients with malignant pleural mesothelioma who were treated from 1993 to 2009.
  • We analyzed a total of 28 patients with malignant pleural mesothelioma.
  • The histological types included 14 epithelial type, 8 biphasic type, and 6 sarcomatoid type.
  • Three patients were classified as stage I, 8 as stage II, 9 as stage III, and 8 as stage IV.
  • Fourteen and eight of the patients underwent systemic chemotherapy and radiotherapy, respectively.
  • The 2-year survival rate of all the patients was 25.7%, and the 2-year survival of the patients with at least one more modalities of the treatments with chemotherapy, radiotherapy and extrapleural pneumonectomy were much higher than those without.
  • We should therefore consider selecting a multimodality treatment for such patients because the administration of either systemic chemotherapy or radiotherapy was found to be associated with a favorable prognosis.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Pneumonectomy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20857819.001).
  • [ISSN] 0387-821X
  • [Journal-full-title] Journal of UOEH
  • [ISO-abbreviation] J. UOEH
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Alvarez JM, Hasani A, Segal A, Sterret G, Millward M, Nowak A, Musk W, Bydder S: Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy. ANZ J Surg; 2009 Oct;79(10):734-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy.
  • BACKGROUND: Trimodality therapy (TMT; extrapleural pneumonectomy (EPP), chemotherapy and radiation therapy) offers the potential of optimal survival in selected patients with Brigham stage I-II epitheliod mesothelioma based on CT, MRI and PET scanning.
  • We hypothesized that these scanning modalities were inadequate to accurately stage these patients.
  • Surgical staging was performed in 30 patients; 24 patients were confirmed as Brigham Stage I-II.
  • However, six were upstaged, five as stage IV disease (one contralateral chest, two contralateral chest and abdomen, two abdomen) and one as mediastinal node positive; two further patients were reclassified histologically (one sarcomatoid, one biphasic).
  • These eight patients fared poorly, 50% dying within 1 year from mesothelioma.
  • [MeSH-major] Laparoscopy / methods. Magnetic Resonance Imaging / methods. Mediastinoscopy / methods. Mesothelioma / diagnosis. Positron-Emission Tomography / methods. Thoracoscopy / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Abdominal Neoplasms / diagnosis. Abdominal Neoplasms / therapy. Adult. Aged. Combined Modality Therapy / methods. Diagnosis, Differential. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / therapy. Male. Middle Aged. Neoplasm Staging. Prognosis. Reproducibility of Results. Retrospective Studies

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19878170.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


13. Giudicelli R: [Surgery for malignant pleural mesothelioma]. Rev Pneumol Clin; 2004 Apr;60(2):68-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgery for malignant pleural mesothelioma].
  • [Transliterated title] Place actuelle de la chirurgie dans le traitement du mésothéliome pleural malin.
  • Malignant pleural mesothelioma (MPM) is an aggressive cancer of the pleura that is usually caused by exposure to asbestos.
  • Current surgical treatment involves in a multimodality regimen with radiation and multiple-drug chemotherapy.
  • All currently proposed therapeutic strategies are in total agreement with the international Mesothelioma Interest Group TNM staging system.
  • Schematically: for stage Ia (early stage disease), the therapeutic approach is generally neo-adjuvant intrapleural treatment using cytikines followed by surgical pleurectomy; for more advanced disease (stage Ib, II and III), a multimodal treatment combining extra-pleural pneumonectomy, radiotherapy and multiple-drug chemotherapy, including in all cases cisplatin, is proposed.
  • Recently, results using this multiple modality approach have been favorable especially for patients with epithelial histology, negative resection margins and no metastases to extrapleural lymph nodes; for stage IV (unresectable tumor), palliative treatment is indicated.
  • Early results have been encouraging and the use of recent drugs should allow more optimal treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / drug therapy. Mesothelioma / surgery. Neoplasm Staging. Pleural Neoplasms / drug therapy. Pleural Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Incidence. Palliative Care. Prognosis. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15133442.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 21
  •  go-up   go-down


14. Okubo K, Sonobe M, Fujinaga T, Shoji T, Sakai H, Miyahara R, Bando T, Date H, Shibuya K, Hiraoka M: Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma. Gen Thorac Cardiovasc Surg; 2009 Nov;57(11):585-90
Kyoto University Research Information Repository - Articles. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma.
  • PURPOSE: Multimodality therapy has been applied to resectable malignant pleural mesothelioma, but the tolerability of the treatment and relapse pattern in detail remain unknown.
  • We reviewed our experience of trimodality therapy as a single-institution study in Japan.
  • METHODS: A total of 16 patients with resectable malignant pleural mesothelioma were intended to treat with extra-pleural pneumonectomy followed by platinum-based chemotherapy and external beam radiation therapy.
  • International Mesothelioma Interest Group staging was stage II in 1, stage III in 11, and stage IV in 4.
  • The tolerability to the combined treatment, the survival, and the relapse pattern were examined.
  • In all, 14 patients received chemotherapy, and subsequently 13 underwent radiotherapy, indicating a tolerability of 81%.
  • In patients with stage III or lower disease, the median survival was 37.9 months.
  • CONCLUSION: Trimodality therapy showed a survival benefit in patients with stage III or lower malignant pleural mesothelioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local. Neoplasms, Mesothelial / therapy. Pleural Neoplasms / therapy. Pneumonectomy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Humans. Japan. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiation Dosage. Radiotherapy, Adjuvant / adverse effects. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Jan;8(1):19-25 [6174494.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Mar;19(3):346-50 [11251277.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Aug;22(2):298-305 [12142203.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Oct;122(4):788-95 [11581615.001]
  • [Cites] Eur J Respir Dis. 1984 Apr;65(3):162-8 [6202538.001]
  • [Cites] Cancer J. 2003 Nov-Dec;9(6):476-84 [14740977.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):25-30 [10458214.001]
  • [Cites] Ann Thorac Surg. 2004 Jul;78(1):245-52 [15223437.001]
  • [Cites] Ann Thorac Surg. 1997 Feb;63(2):334-8 [9033296.001]
  • [Cites] Semin Radiat Oncol. 2003 Jul;13(3):176-81 [12903007.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1157-68 [2666592.001]
  • [Cites] Lung Cancer. 2001 Jan;31(1):57-65 [11162867.001]
  • [Cites] Kyobu Geka. 2007 Jan;60(1):19-24 [17249533.001]
  • [Cites] Ann Thorac Surg. 2007 Nov;84(5):1685-92; discussion 1692-3 [17954086.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1587-92 [17892915.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3451-7 [15337794.001]
  • [Cites] Chest. 1993 Apr;103(4 Suppl):382S-384S [8462330.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):768-75 [12573764.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Br J Cancer. 2002 Aug 27;87(5):491-6 [12189542.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):640-5 [16751058.001]
  • (PMID = 19908112.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Schipper PH, Nichols FC, Thomse KM, Deschamps C, Cassivi SD, Allen MS, Pairolero PC: Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg; 2008 Jan;85(1):257-64; discussion 264
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pleural mesothelioma: surgical management in 285 patients.
  • BACKGROUND: Malignant pleural mesothelioma is a rare, aggressive, and deadly malignancy.
  • Despite increasing incidence, no treatment modality is accepted standard of care.
  • This report analyzes our experience with surgical management of mesothelioma.
  • METHODS: All patients with surgery for mesothelioma from January 1985 through December 2003 were retrospectively reviewed.
  • Twenty patients were stage IA, 82 patients were stage IB, 24 patients were stage II, 75 patients were stage III, 60 patients were stage IV, and 24 patients were of unknown stage.
  • Fifty-three patients (19%) had chemotherapy alone, 16 (5.6%) had radiation alone, and 42 (14.7%) had both.
  • Thirty-day operative mortality was 6.3% and was not significantly associated with the operative procedure (p = 0.79).
  • Fifty-one percent of extrapleural pneumonectomy patients had major complications, significantly greater than patients having any other procedure (p < 0.001).
  • CONCLUSIONS: Extrapleural pneumonectomy can be performed with similar 30-day mortality as other procedures for malignant pleural mesothelioma with a median survival better than subtotal pleurectomy, exploration without resection, and biopsy alone.
  • [MeSH-major] Mesothelioma / pathology. Mesothelioma / surgery. Pleural Neoplasms / pathology. Pleural Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Biopsy, Needle. Confidence Intervals. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Pleura / surgery. Probability. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Sex Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18154820.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


16. Chiappori A, Simon GR, Kvols L, Tetteh L, Mahany JJ, Lush R, Sullivan DM: Phase I trial of carboplatin, irinotecan and etoposide in advanced solid tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):2132

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carboplatin(C), Irinotecan(T) and Etoposide (E) are drugs with a broad spectrum of activity.
  • RESULTS: A total of 10 patients were enrolled from April 2002 to October 2002.Patient characteristics were M/F 5/5; age range 24 to 65, ECOG PS 0/1=1/9; number of prior treatments 0/1/2/3= 4/2/3/1; median number of cycles given=3 (range 1 - 8).
  • Tumor types enrolled were NSCLC = 3, Carcinoid = 3, and 1 each of Head and Neck Cancer, Mesothelioma, Sarcoma and Islet Cell Cancer of the pancreas.
  • In the first cohort of 4 patients, 2 second-cycle grade IV non-febrile neutropenia was observed.
  • Two deaths occurred in previously treated advanced stage NSCLC patients.
  • The subsequent cohort of 6 patients tolerated chemotherapy well with no first-cycle or second-cycle grade III or IV neutropenia or thrombocytopenia.
  • Further dose escalation was not attempted owing to 2/2 patients experiencing Grade IV neutropenia in the first cohort.
  • A phase II trial of extensive stage SCLC is planned with this regimen with correlative intra-tumoral top I and II estimations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016906.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Manente P, Colaut F, Toniolo L, Vicario G, Sartor L, Bortolin M, Visentin P, Scapinello C, Sartori CA: Are you sure to definitely rule out pleurecomy/decortication plus chemotherapy from treatment of malignant pleural mesothelioma? Our experience with 40 cases. J Clin Oncol; 2004 Jul 15;22(14_suppl):7320

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are you sure to definitely rule out pleurecomy/decortication plus chemotherapy from treatment of malignant pleural mesothelioma? Our experience with 40 cases.
  • METHODS: Since 1985 to 2002 40pts with MPM were submitted pleurectomy/decortication combined to intracavitary chemotherapy.Until 1994 intracavitary chemotherapy consisted of Cisplatinum + Ara C(18 pts treated).
  • PS: all pts were<or=to 2 according ECOG scale.25 pts received systemic chemotherapy:16 pts Adryamicin and Mytomicin until 1994.4 pts Carboplatin and IFN alfa since 1995 to 1996.Successively 5 pts received Carboplatin and Gemcitabin.15 pts didn't receive systemic chemotherapy owing to comorbidities.
  • RESULTS: Post-operative staging was performed according to TNM by IMIG 1995 .24pts were stage I,7 pts stage II,4 pts stage III,5 pts stage IV.
  • 2Initial disease(stage Ia and Ib according IMIG).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015083.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Karthaus M, Metzner D, Maher G, Plahl A, Wert N: Pemetrexed + cisplatin (DDP) in patients with malignant peritoneal mesothelioma (AbM). J Clin Oncol; 2004 Jul 15;22(14_suppl):7201

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed + cisplatin (DDP) in patients with malignant peritoneal mesothelioma (AbM).
  • : 7201 Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive neoplasm of the lining of the lung.
  • Only case reports are available for treatment and outcome of AbM.
  • A total of 49 mesothelioma pts with stage III/IV were observed between 12/02 and 11/03.
  • Pts received pemetrexed based therapy including dexamethasone prophylaxis for skin rash on day -1 to+2 additionally.
  • Study endpoints were response (RR), time to progression (TTP) and safety.
  • RESULTS: Four pts (1 AbM, 1 MPM, 2 MPM+AbM) were excluded due to renal impairment (n=1) or death prior to chemotherapy (n=3).
  • 45 mesothelioma pts (34 m/11 f) were treated with pemetrexed.
  • Staging revealed AbM in 11 pts, MPM in 30 pts, while 4 pts had malignant mesothelioma on both sites of the diaphragma.
  • Major toxicities (WHO >°III/IV) were nausea and neutropenia (2/11).
  • Treatment and response data are given in the table below.
  • CONCLUSIONS: Pemetrexed in combination with DDP is a well tolerable and active regimen for advanced peritoneal malignant mesothelioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013854.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Arrieta O Sr, Medina LA Sr, Guzmán E, Rios Trejo MA Sr, Mendoza D, Astorga Ramos A, Martinez Barrera L, Hernández Pedro N, Arechaga Ocampo E, De la Garza J: Liposomal doxorubicin and cisplatin as first-line chemotherapy in unresectable malignant pleural mesothelioma: A phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):e13507

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposomal doxorubicin and cisplatin as first-line chemotherapy in unresectable malignant pleural mesothelioma: A phase II study.
  • : e13507 Background: Malignant pleural mesothelioma (MPM) is a poor prognosis neoplasm.
  • Its worldwide incidence is rising but until recently chemotherapy has not been shown to be effective in its treatment.
  • The combination of cisplatin and pemetrexed is the approved "standard" treatment in unresectable MPM.
  • METHODS: From September 2006 to October 2008, consecutive patients with stage III / IV MPM were included to receive LD 40 mg/m<sup>2</sup> and Cis 60 mg/m<sup>2</sup> every 21 days for a maximum of 4 cycles.
  • Gamma camera images (GCI) of Tc-99m-labeled LD were acquired to evaluate LD accumulation in measurable tumor tissue.
  • RESULTS: Twenty seven patients were included, 81.5% were stage III and 18.5% were IV.
  • Median time to progression was 5.0 ± 1.1 months (CI 95%, 2.7-7.3).
  • GCI showed good accumulation and retention (60%) of the labeled LD in tumor tissue at 4 h after the initial injection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961260.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Brechot JM, Morère JF, Des Guetz G, Chouhania K, Breau JL: Chemotherapy with gemcitabine and oxaliplatin in 13 malignant pleural mesothelioma (MPM): A monocenter experience. J Clin Oncol; 2004 Jul 15;22(14_suppl):7250

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy with gemcitabine and oxaliplatin in 13 malignant pleural mesothelioma (MPM): A monocenter experience.
  • This chemotherapy has been administered in clinical practice in our department for 2 years.
  • RESULTS: 13 pts (9 males, 4 females), mean age 62y (50-74), PS 0-1 12 pts, PS 2 1 pt, with a MPM diagnosed by pleuroscopy (9), thoracotomy (1) or blind pleural biopsy (3), with epithelial (4), mixed (4) and unspecified (5) histological subtype, all stage III or IV, received as outpatient treatment an association of gemcitabine 1000mg/m<sup>2</sup> D1 and oxaliplatin 100mg/m<sup>2</sup> D2 every 2 weeks with a mean of 8 cycles.
  • Median time to progression (TTP) was 7,5 months.
  • In 5 cases, treatment was discontinued because of non hematologic toxicities (allergia grade 3 in 2 pts at the 6<sup>th</sup> and 7<sup>th</sup>cycles, peripheral neurotoxicity in 3 pts (at the 6<sup>th</sup> and 10<sup>th</sup> cycles).
  • CONCLUSION: GEMOX is a well tolerated and active chemotherapy regimen in MPM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013915.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Pinto C, Marino A, Guaraldi M, Melotti B, Piana E, Martoni A, Pannuti F: Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol; 2001 Apr;24(2):143-7
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study.
  • The prognosis of malignant pleural mesothelioma is poor, with a median survival time from diagnosis of 7 to 17 months.
  • At present there is no standardized treatment of this neoplasia.
  • Between July 1995 and January 1999, 22 patients with malignant pleural mesothelioma were enrolled in our study.
  • The characteristics of patients were: 16 men and 6 women; median age 61 years (range, 49-77 years); stage (according to Butchart): 8 patients stage I, 10 stage II, 2 stage III, and 2 stage IV; cytologic diagnosis in 5 cases and histologic diagnosis in 17 cases.
  • The treatment consisted of mitoxantrone 10 mg/m2 intravenous (IV) or intrapleural (IPL), methotrexate 35 mg/m2 IV, and mitomycin 7 mg/m2 IV on day 1 and repeated every 3 weeks, with mitomycin in alternate cycles (MMM regimen).
  • One complete response (4.5%) (42 months of duration) and 6 partial responses (27.3%) (5, 5, 7, 9, 14, and 19 months of duration) were achieved; the overall response rate (ORR) was 31.8% (95% CI, 12.4-51.3%); 7 patients were stable under this treatment (31.8%).
  • According to the pathologic type, ORR for the only epithelial type was 39.9% (95% CI, 15.2-64.8%).
  • Median time to progression was 6 months (range, 1-22).
  • The overall median survival time was 13.5 months (range, 1-50); the median survival time of responders significantly differed from that of nonresponders (18.0 versus 8.5 months; p = 0.017).
  • This treatment produced a considerable clinical benefit, with improvement of dyspnea (68.4%) and pain (33.3%); 15 of 19 patients (78.9%) with pleural effusion at the time of diagnosis showed an important reduction in pleural fluid during chemotherapy.
  • Hematologic toxicity was the main side effect; World Health Organization grade III to IV of neutropenia, anemia, and thrombocytopenia were observed in 81.8%, 13.6%, and 22.7% of patients, respectively.
  • From the data presented here, this regimen can be considered active in the treatment of malignant pleural mesothelioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11319288.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; BZ114NVM5P / Mitoxantrone; YL5FZ2Y5U1 / Methotrexate; MMM protocol 2
  •  go-up   go-down


22. Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM: Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol; 2000 Dec 01;18(23):3912-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
  • PURPOSE: To evaluate the response rate and impact on quality of life of vinorelbine given as cycles of 30 mg/m(2) weekly for 6 weeks to patients with malignant pleural mesothelioma.
  • PATIENTS AND METHODS: Twenty-nine patients with histologically proven malignant pleural mesothelioma were enrolled (26 male patients and three female patients; median age, 58 years [range, 29 to 77 years]).
  • The International Mesothelioma Interest Group staging system was used: one patient had stage Ib disease, 10 had stage II disease, eight had stage III disease, and 10 had stage IV disease.
  • The new guidelines to evaluate the response to treatment in solid tumors were used.
  • Responses were measured by spiral computed tomography scan.
  • There were seven partial responses (24% [95% confidence interval, 10% to 44%]), 16 patients had stable disease (55%), and six patients had disease progression on therapy (21%).
  • Quality-of-life analyses showed a benefit for vinorelbine therapy.
  • CONCLUSION: Vinorelbine shows promise in the palliation of patients with malignant pleural mesothelioma.
  • The relatively low toxicity of the drug suggests that trials of vinorelbine in combination with other agents should be feasible.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy. Vinblastine / analogs & derivatives. Vinblastine / therapeutic use
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Quality of Life. Survival Rate

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11099320.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


23. Portalone L, Antilli A, Nunziati F, Crispino C, de Marinis F, Friggeri L, Lombardi A, Lorusso V, Pronzato P, Sambiasi D, Signora M, Associazione Italiana Pneumologi Ospedalieri Thoracic Oncology Study Group: Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma. Tumori; 2005 Jan-Feb;91(1):15-8
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma.
  • Malignant pleural mesothelioma represents a rare disease, for which chemotherapy actually remains unsatisfactory.
  • They were treated with epirubicin (100 mg/m2 iv on day 1) plus gemcitabine (1000 mg/m2 iv on days 1 and 8) every 4 weeks for 6 cycles.
  • Patients who responded to chemotherapy (n = 6) were subsequently treated with interleukin-2 (4,500,000 IU) subcutaneously every other day, until progression.
  • According to WHO criteria, we observed grade III-IV hematological and gastrointestinal toxicity respectively in 3 patients (11%) and 1 patient (3%).
  • Two patients (8%) could not be evaluated for response (no therapy performed).
  • In 26 patients, the median survival was 55 weeks (range, 7-222) and median time to progression 30 weeks (range, 4-156).
  • At the time of this writing, no patient is alive.
  • All patients were at stage III, and time to progression was 58 weeks and survival 63.5 weeks, without any toxicity.
  • This multi-center phase II clinical trial showed that epirubicin plus gemcitabine, as a first-line treatment in malignant pleural mesothelioma, has promising activity with a good tolerability profile and symptom palliation.
  • The role of interleukin-2 in maintenance therapy for malignant pleural mesothelioma is encouraging and requires further study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Disease Progression. Drug Administration Schedule. Epirubicin / administration & dosage. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15849999.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


24. Shukuya T, Takahashi T, Nakamura Y, Yamamoto N: [A case of malignant pleural mesothelioma that responded to cisplatin plus pemetrexed rechallenge]. Gan To Kagaku Ryoho; 2010 Mar;37(3):487-90
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant pleural mesothelioma that responded to cisplatin plus pemetrexed rechallenge].
  • We present a case of malignant pleural mesothelioma which responded to a cisplatin plus pemetrexed rechallenge.
  • A 78- year-old man was diagnosed as stage IV malignant pleural mesothelioma in International Mesothelioma Interest Group (IMIG) stage by biopsy using ultrasonography and chest to abdominal CT.
  • After this treatment, all of the lesions shrank, and the best overall response was partial response (PR) in Response Evaluation Criteria in Solid Tumors (RECIST).
  • Cisplatin plus pemetrexed was administered as fifth-line chemotherapy again, the lesions shrank, and the best overall response was PR in RECIST.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332689.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Knuuttila A, Ollikainen T, Halme M, Mali P, Kivisaari L, Linnainmaa K, Jekunen A, Mattson K: Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study. Anticancer Drugs; 2000 Apr;11(4):257-61
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study.
  • We chose to treat malignant pleural mesothelioma with a combination of docetaxel and irinotecan (CPT-11), because there have been preliminary reports that CPT-11 is active against mesothelioma, and docetaxel and CPT-11 were the most active agents in our in vitro experiments in human mesothelioma cell lines.
  • Fifteen previously untreated patients with pleural mesothelioma (IMIG Stage III-IV) were given docetaxel 60 mg/m2 followed by CPT-11 190 mg/m2 on day 1, repeated every 3 weeks.
  • Three patients had stable disease (23%); median time to progression was 7 months.
  • Median survival in all the patients was 8.5 months from the first chemotherapy cycle and 11 months from diagnosis.
  • We do not recommend the combination of docetaxel and CPT-11 using the schedule presented here for further investigation in malignant mesothelioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Mesothelioma / drug therapy. Paclitaxel / analogs & derivatives. Pleural Neoplasms / drug therapy. Taxoids
  • [MeSH-minor] Aged. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10898540.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; 7673326042 / irinotecan; P88XT4IS4D / Paclitaxel; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


26. Shia J, Qin J, Erlandson RA, King R, Illei P, Nobrega J, Yao D, Klimstra DS: Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases. Virchows Arch; 2005 Nov;447(5):828-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases.
  • Mesothelioma with a pronounced myxoid stroma has been identified as a morphological pattern that might portend a better prognosis.
  • Reports on this type of cases are few.
  • The inclusion criteria were mesotheliomas with at least 50% of the tumor exhibiting a pronounced myxoid stroma that occupied more than 50% of the tumor volume (designated as myxoid mesothelioma).
  • Patients presented at various stages [International Mesothelioma Interest Group (IMIG) stage II, 4; stage III, 9; and stage IV, 6].
  • Most (16/19) patients were treated by extrapleural pneumonectomy with adjuvant radiation or chemotherapy or both.
  • Overall, the median survival rate was 36 months (median follow-up time, 17 months), and the 2-year survival rate was 79%.
  • The myxoid material stained positive for Alcian blue, and the staining diminished after treatment with hyaluronidase in 12 of 12 cases.
  • Ultrastructurally, all six tumors examined had typical mesothelial-type surface microvilli and a moderately electron-dense extracellular amorphous material that often formed a haze enmeshing the surface microvilli.
  • Hyaluronic acid-type, fern-like crystals were noted in all cases.
  • [MeSH-major] Mesothelioma / pathology. Pleural Neoplasms / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Oncol. 2003 Mar;15(2):127-30 [12601276.001]
  • [Cites] Ultrastruct Pathol. 1996 Jul-Aug;20(4):293-325 [8837337.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Oct;122(4):788-95 [11581615.001]
  • [Cites] Oncologist. 1999;4(6):488-500 [10631693.001]
  • [Cites] Ultrastruct Pathol. 2002 Nov-Dec;26(6):355-63 [12537760.001]
  • [Cites] Ann Thorac Surg. 1999 Nov;68(5):1799-804 [10585061.001]
  • [Cites] Thorax. 1976 Feb;31(1):15-24 [1257933.001]
  • [Cites] Ann Diagn Pathol. 2002 Jun;6(3):164-7 [12089727.001]
  • [Cites] Hum Pathol. 1989 Apr;20(4):400 [2467873.001]
  • [Cites] Lung Cancer. 1996 Feb;14(1):1-12 [8696713.001]
  • [Cites] J Submicrosc Cytol. 1981 Jul;13(3):483-500 [7038137.001]
  • [Cites] Chest. 1996 Jan;109(1):109-14 [8549169.001]
  • [Cites] Am J Clin Pathol. 1992 Apr;97(4):498-502 [1553915.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(6):445-51 [8333148.001]
  • [Cites] Arch Pathol Lab Med. 1992 Aug;116(8):874-80 [1341882.001]
  • [Cites] Histopathology. 2000 Jul;37(1):33-6 [10931216.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Apr;111(4):815-25; discussion 825-6 [8614142.001]
  • [Cites] Ultrastruct Pathol. 2004 Jul-Aug;28(4):213-28 [15693633.001]
  • [Cites] Thorax. 1997 Jun;52(6):507-12 [9227715.001]
  • [Cites] Pathol Res Pract. 2001;197(4):253-6 [11358011.001]
  • (PMID = 16021506.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


27. Rice DC, Stevens CW, Correa AM, Vaporciyan AA, Tsao A, Forster KM, Walsh GL, Swisher SG, Hofstetter WL, Mehran RJ, Roth JA, Liao Z, Smythe WR: Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg; 2007 Nov;84(5):1685-92; discussion 1692-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
  • BACKGROUND: Malignant pleural mesothelioma is a locally aggressive tumor that is usually fatal.
  • To improve local control, we have used intensity-modulated radiation therapy (IMRT) as it allows better dose distribution to regions at risk of recurrence as well as reduced radiation to surrounding organs.
  • At a median interval of 2.5 months from surgery, 63 patients received IMRT (median dose 45 Gy) with curative intent.
  • Chemotherapy was not routinely administered.
  • American Joint Committee on Cancer pathology stage was I in 6 patients (6%), II in 7 (7%), III in 72 (72%), and IV (T4) in 15 (15%).
  • CONCLUSIONS: Intensity-modulated radiation therapy after EPP results in excellent local control for malignant pleural mesothelioma; however, distant metastases remain a significant problem and limit survival.
  • This provides a strong rationale for combining aggressive local regimens with systemic therapy.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy. Pneumonectomy / methods. Radiotherapy, Intensity-Modulated
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications / epidemiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954086.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


28. Castagneto B, Zai S, Mutti L, Lazzaro A, Ridolfi R, Piccolini E, Ardizzoni A, Fumagalli L, Valsuani G, Botta M: Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients. Lung Cancer; 2001 Feb-Mar;31(2-3):303-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.
  • Malignant pleural mesothelioma is often unresectable at diagnosis, is refractory to cytotoxic agents and is frequently complicated by pleural effusion.
  • The expected survival range for patients with or without involvement of visceral pleura is respectively 1-9 and 9-12 months; mesothelioma-related pleural effusion severely impairs the patients' quality of life and easily relapses after conservative treatments.
  • Intrapleural administration of IL-2 is reported to be effective both in tumor-associated malignant pleurisy and on primary mesothelioma, whereas few data exist about IL-2 systemic administration.
  • In order to assess the palliative and therapeutic activity of IL-2 in unresectable pleural malignant mesothelioma with pleural effusion, we performed a phase II study on 31 consecutive patients (M/F 16/15; median age 61 years, range 40-84; PS ECOG 0 n=7; ECOG 1 n=15; ECOG 2 n=9; stage IA n=13; IB n=9; II n=7; IV=2) who received first-line therapy with intrapleural repeated instillation of 9000000 I.U.
  • Toxicity (WHO criteria) with intrapleural IL-2 consisted of grade 3 fever in 6/31 (19%) patients and of cardiac toxicity (failure) grade 3 in one patient (3%); toxicity during subcutaneous treatment was mild to moderate, mainly a flu-like syndrome.
  • IL-2 intrapleural administration followed by low-dose IL-2 subcutaneously in pleurisy-complicated malignant mesothelioma is feasible and active both in palliation of pleural effusion and on primary tumor, with manageable toxicity.
  • [MeSH-major] Interleukin-2 / therapeutic use. Mesothelioma / drug therapy. Pleural Effusion / drug therapy. Pleural Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11165411.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Interleukin-2
  •  go-up   go-down


29. Shoji T, Tanaka F, Yanagihara K, Inui K, Wada H: Phase II study of repeated intrapleural chemotherapy using implantable access system for management of malignant pleural effusion. Chest; 2002 Mar;121(3):821-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of repeated intrapleural chemotherapy using implantable access system for management of malignant pleural effusion.
  • STUDY OBJECTIVE: To examine the effectiveness of repeated intrapleural chemotherapy using an implantable access system (INFUSE-A-PORT; Horizon Medical Products; Manchester, GA) for the management of a malignant pleural effusion (MPE).
  • There were 17 patients with MPEs resulting from primary lung cancer; of whom 7 had metastatic disease (stage IV), 3 had stage IIIB disease, and 7 had postoperative recurrences.
  • Three patients had MPEs that were caused by mesothelioma, and two had MPEs caused by breast cancer.
  • Intrapleural catheters were placed by a video-assisted thoracoscopic procedure.
  • No treatment-related mortality, renal dysfunction, bone marrow suppression, or infection occurred.
  • CONCLUSIONS: Repeated intrapleural chemotherapy using the implantable access system is useful and safe for patients with MPEs.
  • In the future, prospective randomized studies will be necessary to compare the efficacy of therapy for MPE using the implantable access system with that of pleurodesis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Infusion Pumps, Implantable. Pleural Effusion, Malignant / drug therapy

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11888966.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


30. Vokes EE, Perry MC, Kindler HL, Green MR: The cancer and leukemia group B respiratory committee. Clin Cancer Res; 2006 Jun 1;12(11 Pt 2):3581s-8s
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Cancer and Leukemia Group B Respiratory Committee has a 30-year track record of clinical investigation in patients with small-cell lung cancer and non-small-cell lung cancer (NSCLC) and mesothelioma.
  • The most widely recognized contributions of the Committee include the early confirmation of the role of concurrent chemoradiotherapy in LD-SCLC, the effect of combination chemotherapy followed by radiation in stage III NSCLC, the introduction of third-generation agents into concurrent chemoradiation for stage III disease, the prospective demonstration of the benefit of treating older (70 years old) and poorer performance status (performance status = 2) patients with first-line combinations for stage IV disease, and the development of the "Herndon prognostic index" to normalize patient characteristics and outcomes in sequential phase II trials of new agents in patients with mesothelioma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Carcinoma, Small Cell / therapy. Lung Neoplasms / therapy. Mesothelioma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Humans. Leukemia / therapy. Neoplasms / therapy. Radiotherapy. Societies, Medical

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740789.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 64
  •  go-up   go-down


31. Das P, Ng AK, Stevenson MA, Mauch PM: Clinical course of thoracic cancers in Hodgkin's disease survivors. Ann Oncol; 2005 May;16(5):793-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our goal was to evaluate the prognosis and treatment outcomes of thoracic cancers after Hodgkin's disease.
  • PATIENTS AND METHODS: Thirty-three patients treated for Hodgkin's disease at Harvard-affiliated hospitals subsequently developed small-cell lung carcinoma, non-small-cell lung carcinoma (NSCLC) or mesothelioma.
  • Information was obtained from medical records about the initial treatment for Hodgkin's disease, any salvage therapy, smoking history, and the stage, histology, treatment and survival for thoracic cancers.
  • RESULTS: Of the 33 patients, 29 (88%) had a history of radiotherapy to the thorax, 17 (52%) had received alkylating chemotherapy, and 24 (73%) had a known history of smoking.
  • The median time between diagnosis of Hodgkin's disease and diagnosis of thoracic cancer was 17.3 years (range 1.2-27.9 years).
  • Among patients with NSCLC and a known stage, 85% presented with stage III or stage IV disease.
  • Among patients whose treatment details were available, 40% underwent surgery, 40% received radiotherapy and 65% received chemotherapy.
  • CONCLUSIONS: Most patients with thoracic cancers after Hodgkin's disease have a history of exposure to risk factors and present at an advanced stage.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15802277.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Dickgreber NJ, Sorensen JB, Paz-Ares LG, Schytte TK, Latz JE, Schneck KB, Yuan Z, Sanchez-Torres JM: Pemetrexed safety and pharmacokinetics in patients with third-space fluid. Clin Cancer Res; 2010 May 15;16(10):2872-80
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Pemetrexed is established as first-line treatment with cisplatin for malignant pleural mesothelioma and advanced nonsquamous non-small-cell lung cancer (NSCLC) and as single-agent second-line treatment for nonsquamous NSCLC.
  • EXPERIMENTAL DESIGN: Patients with TSF (pleural effusions, ascites) and relapsed, stage III/IV NSCLC or malignant pleural/peritoneal mesothelioma were treated with pemetrexed (500 mg/m2) on day 1 of each 21-day cycle.
  • TSF was drained at any time only if clinically indicated.
  • Seven grade 3/4 drug-related toxicities, including four hematologic, were reported; there were no treatment-related deaths.
  • There was no correlation between TSF amount and type, number, and sequelae of toxicities.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Ascites / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / pharmacokinetics. Guanine / analogs & derivatives. Mesothelioma / drug therapy. Pleural Effusion, Malignant / drug therapy
  • [MeSH-minor] Adult. Aged. Humans. Lung Neoplasms / complications. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Middle Aged. Neoplasm Staging. Pemetrexed. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology. Pleural Neoplasms / complications. Pleural Neoplasms / drug therapy. Pleural Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 AACR.
  • (PMID = 20460481.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


33. Bunn PA Jr: Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors). Semin Oncol; 2002 Jun;29(3 Suppl 9):17-22
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors).
  • Recent developments in the armamentarium of chemotherapeutic agents for lung cancer have shown that two-drug combinations improve survival, relieve symptoms, and improve quality of life; however, complete response rates are still approximately 1% in stage IV disease and less than 20% of advanced stage patients survive 2 years.
  • Therefore, improved therapeutic agents that increase efficacy are sorely needed.
  • The multitargeted antifolate, pemetrexed (Alimta; Eli Lilly and Co, Indianapolis, IN) was developed because it inhibits multiple enzymes involved in DNA synthesis including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase.
  • Subsequent studies described in this article will show that these toxicities can be significantly reduced by the use of vitamin supplementation with folate and B12, and that pemetrexed has considerable activity in non-small cell lung cancer and mesothelioma.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Enzyme Inhibitors / therapeutic use. Glutamates / therapeutic use. Guanine / therapeutic use. Lung Neoplasms / drug therapy. Thymidylate Synthase / antagonists & inhibitors
  • [MeSH-minor] Carboplatin / administration & dosage. Cisplatin / administration & dosage. Clinical Trials as Topic. Drug Screening Assays, Antitumor. Folic Acid / metabolism. Humans. Mesothelioma / drug therapy. Pemetrexed. Pleural Neoplasms / drug therapy. Vitamin B 12 / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12094334.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 46934; United States / NCI NIH HHS / CA / CA 58187
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Enzyme Inhibitors; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 0W860991D6 / Deoxycytidine; 5Z93L87A1R / Guanine; 935E97BOY8 / Folic Acid; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; EC 2.1.1.45 / Thymidylate Synthase; P6YC3EG204 / Vitamin B 12; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 26
  •  go-up   go-down


34. Schallier D, Decoster L, Fontaine C, De Grève J: Pemetrexed-induced eyelid edema: incidence and clinical manifestations. Anticancer Res; 2010 Dec;30(12):5185-8
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pemetrexed-induced eyelid edema is a rare side-effect of pemetrexed treatment.
  • RESULTS: Eighty-six patients received pemetrexed-containing chemotherapy either as a single agent (45 patients) or in combination with cis- or carboplatin (41 patients).
  • Two patients (2.3%) with stage IV non-small cell lung cancer (NSCLC) presented the edema typically localized in the lower eyelid after first-line treatment with carboplatin-pemetrexed.
  • The edema remained identical in both patients during treatment and regressed in one patient in whom treatment was withdrawn.
  • The physiopathological mechanism and, as a consequence, the treatment and/or prevention of this apparently benign side-effect remains unknown.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carboplatin / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Eyelids / drug effects. Female. Humans. Lung Neoplasms / drug therapy. Male. Mesothelioma / drug therapy. Middle Aged. Pemetrexed. Retrospective Studies

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Eyelid Disorders.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187510.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


35. Génébès C, Brouchet L, Kamar N, Lepage B, Prévot G, Rostaing L, Didier A, Mazières J: Characteristics of thoracic malignancies that occur after solid-organ transplantation. J Thorac Oncol; 2010 Nov;5(11):1789-95
MedlinePlus Health Information. consumer health - Organ Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Among a cohort of 2831 patients who received a transplant at our institution and were followed between 1984 and 2009, 24 patients (0.85%) developed thoracic malignancies.
  • The most frequent histologic types were squamous cell carcinoma (n = 11, 46%) and adenocarcinoma (n = 9, 37%).
  • The median time period between transplantation and diagnosis of lung cancer was 6.6 years.
  • Seven patients underwent surgery, three had radiotherapy, four had chemotherapy, and six had multimodal treatment.
  • The median survival time was 1.5 years, ranging from 6 months for stage IV to 3.7 years for stage I.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma, Squamous Cell / etiology. Lung Neoplasms / etiology. Mesothelioma / etiology. Organ Transplantation / adverse effects. Small Cell Lung Carcinoma / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20975378.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Stathopoulos GP, Dimitroulis J, Toubis M, Katis C, Karaindros D, Stathopoulos J, Koutandos J: Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: a phase I-II trial. Lung Cancer; 2007 Jul;57(1):66-71
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pemetrexed, a novel multi-targeted agent established for the treatment of mesothelioma, has been under investigation for other malignancies, and in recent years particularly for non-small-cell lung cancer (NSCLC).
  • In the present trial we investigated pemetrexed in combination with paclitaxel as front-line treatment in advanced or metastatic NSCLC.
  • There were 39 males and nine females, median age 62 years (range 37-81 years), one patient stage IIIA N(2), 23 patients, IIIB and 24, stage IV.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alopecia / chemically induced. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / toxicity. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / toxicity. Asthenia / chemically induced. Female. Follow-Up Studies. Glutamates / administration & dosage. Glutamates / toxicity. Guanine / administration & dosage. Guanine / analogs & derivatives. Guanine / toxicity. Humans. Male. Middle Aged. Nausea / chemically induced. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Paclitaxel / administration & dosage. Paclitaxel / toxicity. Pemetrexed. Survival Analysis. Time Factors. Vomiting / chemically induced

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17382431.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement